CLINICAL TRIALS PROFILE FOR PRILOCAINE HYDROCHLORIDE
✉ Email this page to a colleague
505(b)(2) Clinical Trials for PRILOCAINE HYDROCHLORIDE
Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|---|
New Formulation | NCT01073371 ↗ | Anesthetic Efficacy of Liposomal Prilocaine in Maxillary Infiltration Anesthesia | Completed | Conselho Nacional de Desenvolvimento Científico e Tecnológico | Phase 1 | 2008-07-01 | This blinded randomized, crossover, three period study aim to evaluate the anesthetic efficacy of liposome-encapsulated 3% prilocaine compared to 3% plain prilocaine and 3% prilocaine with 0,03IU/mL felypressin, after 1.8mL infiltration in the buccal sulcus of the maxillary right canine, in 32 volunteers. |
New Formulation | NCT01073371 ↗ | Anesthetic Efficacy of Liposomal Prilocaine in Maxillary Infiltration Anesthesia | Completed | Fundação de Amparo à Pesquisa do Estado de São Paulo | Phase 1 | 2008-07-01 | This blinded randomized, crossover, three period study aim to evaluate the anesthetic efficacy of liposome-encapsulated 3% prilocaine compared to 3% plain prilocaine and 3% prilocaine with 0,03IU/mL felypressin, after 1.8mL infiltration in the buccal sulcus of the maxillary right canine, in 32 volunteers. |
New Formulation | NCT01073371 ↗ | Anesthetic Efficacy of Liposomal Prilocaine in Maxillary Infiltration Anesthesia | Completed | University of Campinas, Brazil | Phase 1 | 2008-07-01 | This blinded randomized, crossover, three period study aim to evaluate the anesthetic efficacy of liposome-encapsulated 3% prilocaine compared to 3% plain prilocaine and 3% prilocaine with 0,03IU/mL felypressin, after 1.8mL infiltration in the buccal sulcus of the maxillary right canine, in 32 volunteers. |
>Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for PRILOCAINE HYDROCHLORIDE
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00154167 ↗ | Safety and Efficacy Study of NV-101 in Dental Patients | Completed | Novalar Pharmaceuticals, Inc. | Phase 2 | 2003-02-01 | The purpose of this study was: - to determine if NV-101 accelerates recovery from numbness compared to placebo - to evaluate safety of NV-101 |
NCT00355277 ↗ | Local Anaesthetic Effects of Transcutaneous Amitriptyline | Completed | University Hospital, Clermont-Ferrand | Phase 1 | 2005-11-01 | The aim of this study is to assess the local anaesthetic effects of amitriptyline applied on the skin of human volunteers, considering the differential effects on mechanic and thermic sensitivity, the local and general tolerance, and the systemic absorption of the drug. The solution used for dilution of amitriptyline is the only one known to allow transcutaneous absorption of the drug [1]. Considering that the peripheral sensitive fibre is a possible site of action of tricyclic antidepressants for relieving neuropathic pain [2,3], this is a first step study before further assessment of the therapeutic effects of transcutaneous amitriptyline. |
NCT00408941 ↗ | EEG and Auditory Evoked Potentials During Local Anesthesia | Unknown status | Technische Universität München | Phase 4 | 2006-12-01 | The aim of the present study was to investigate the sensitivity of AEP (auditory evoked potentials) to muscular artefacts using sedation and local anesthesia. |
NCT00444626 ↗ | A Study to Compare the Safety and Effectiveness of a Non-FDA Approved Device Dermal Gel Extra (DGE) and an FDA Approved Device for the Correction of Nasolabial Folds (NLFs) | Completed | Mentor Worldwide, LLC | Phase 3 | 2007-05-01 | The purpose of this research study is to evaluate the safety and effectiveness of injection with DGE Injectable Gel (hyaluronic acid with lidocaine manufactured by Genzyme Biosurgery) as compared to injection with Restylane (a Food and Drug Administration (FDA) approved dermal filler) in patients undergoing cutaneous correction of the nasolabial folds (NLFs). |
NCT00444626 ↗ | A Study to Compare the Safety and Effectiveness of a Non-FDA Approved Device Dermal Gel Extra (DGE) and an FDA Approved Device for the Correction of Nasolabial Folds (NLFs) | Completed | Genzyme, a Sanofi Company | Phase 3 | 2007-05-01 | The purpose of this research study is to evaluate the safety and effectiveness of injection with DGE Injectable Gel (hyaluronic acid with lidocaine manufactured by Genzyme Biosurgery) as compared to injection with Restylane (a Food and Drug Administration (FDA) approved dermal filler) in patients undergoing cutaneous correction of the nasolabial folds (NLFs). |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for PRILOCAINE HYDROCHLORIDE
Condition Name
Clinical Trial Locations for PRILOCAINE HYDROCHLORIDE
Trials by Country
Clinical Trial Progress for PRILOCAINE HYDROCHLORIDE
Clinical Trial Phase
Clinical Trial Sponsors for PRILOCAINE HYDROCHLORIDE
Sponsor Name